As it is known that genetic polymorphisms of glutathione S-transferases (GST)
have been associated with a variety of human diseases including cancer, we
have analyzed the impact of GSTT1 and GSTM1 null genotypes on the risk of
development of differentiated thyroid cancer (DTC) and cytogenetic changes
in peripheral blood lymphocytes of DTC patients before and after radioiodine
therapy. The polymorphism of GSTT1 and GSTM1 genes were genotyped using
multiplex polymerase chain reaction (PCR) and cytokinesis - block
micronucleus (MN) assay to assess cytogenetic changes. GSTT1 and GSTM1 null
were predominantly found in patients, but statistical significance was
observed only for GSTT1 null. The null genotypes increased risk of
development of DTC; GSTT1 null a 4.5 times (p < 0.05), GSTM1 null about 3
times but on the border of statistical significance (p = 0.057), while
combination of dual null genotypes almost 7 times (p < 0.05) increased risk.
No significant effects of the null genotypes as well as their interactions
with potential modifiers of MN (diagnose, age, gender and smoking habits)
were observed on both baseline and radioiodine-induced values of MN and
cytokinesis block proliferation index (CBPI) in DTC patients. Results
suggest that both GSTT1 and GSTM1 null genotypes increased risk for DTC but
to a greater extent GSTT1 null. Null genotypes of GSTT1 and GSTM1 did not
have potential to influence baseline and radioiodine-induced values of MN
and CBPI, so that absence of T1 and M1 isoenzymes did not cause increased
mutagen sensitivity of PBLs of DTC patients.
P09 CYTOGENETIC CHANGES IN PERIPHERAL BLOOD LYMPHOCYTES OF PATIENTS ON HEMODIALYSIS INFECTED WITH HEPATITIS C
